7
Registered trials
4
Recruiting
6
Unique sponsors
6
Unique IMPs
4
Commercial trials
Drug classes (ATC)
—
ATC code not specified
5
B
Haematology (ATC B)
1
J
Anti-infectives (ATC J)
2
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Monoclonal antibody
1 substance
Fluoroquinolone
1 substance
Supportive / diluent
1 substance
Phase II:
5
Phase III/IV:
1
Phase IV:
1
Phase II
5 trials-
EndedBoehringer Ingelheim International GmbH CommercialBI 1291583
-
RecruitingBoehringer Ingelheim International GmbH CommercialBI 1291583
-
RecruitingGSK PLC CommercialHUMAN IGG1 MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-33
-
EndedSanofi-Aventis Recherche & Developpement CommercialITEPEKIMAB
-
RecruitingPhilipps-Universitaet Marburg AcademicCOLISTIMETHATE SODIUM
Phase III/IV
1 trial-
PendingFundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau AcademicCIPROFLOXACIN; COLISTIMETHATE SODIUM; SODIUM CHLORIDE
Phase IV
1 trial-
RecruitingHospital Universitari De Girona Doctor Josep Trueta AcademicIMP not specified
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | Commercial | 2 | Phase II | 1 |
| GSK PLC | Commercial | 1 | Phase II | 1 |
| Sanofi-Aventis Recherche & Developpement | Commercial | 1 | Phase II | 0 |
| Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau | Academic | 1 | Phase III/IV | 0 |
| Philipps-Universitaet Marburg | Academic | 1 | Phase II | 1 |
| Hospital Universitari De Girona Doctor Josep Trueta | Academic | 1 | Phase IV | 1 |
New trials by year
2022
1
2023
1
2024
3
2026
1